Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Saint-Herblain – page 34

611 clinical trials in Saint-Herblain, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Saint-Herblain at a glance
611
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

611 trials in Saint-Herblain

Open in trial search

Oesophageal adenocarcinoma

Not recruiting

Study on Reducing Chemotherapy for Patients with Low-Risk Localized Gastroesophageal Cancer Using Docetaxel, Oxaliplatin, Calcium Folinate, and Fluorouracil

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Centre Leon Berard

Squamous cell carcinoma of head and neck

Not recruiting

Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Squamous cell carcinoma of head and neck

Not recruiting

Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Groupe Oncologie Radiotherapie Tete Cou

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Not recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Neuroendocrine carcinoma of the skin+9

Not recruiting

Study on Reduced Dose Intensity of Pembrolizumab and Drug Combination for Patients with Advanced or Metastatic Cancer Responding to Standard Immunotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Unicancer

Colorectal cancer metastatic

Not recruiting

Study of Pembrolizumab with Drug Combination for Patients with Microsatellite Stable Metastatic Colorectal Cancer with High Immune Infiltrate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Fondation Franc.Cancerologie Digestive

Prostate cancer

Not recruiting

Study on Apalutamide with Radiotherapy and Hormone Therapy for High-Risk Prostate Cancer Patients with Rising PSA After Surgery

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Unicancer

Hormone-refractory prostate cancer+2

Not recruiting

Study on Capivasertib and Docetaxel for Treating Metastatic Castration-Resistant Prostate Cancer in Patients

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:AstraZeneca AB

Acute kidney injury

Not recruiting

Study on TIN816 for Preventing Acute Kidney Injury in Adults Undergoing Cardiac Surgery

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:TIN816
  • Sponsor:Novartis Pharma AG

Prostate cancer

Not recruiting

Study on Darolutamide with Radiation Therapy for Patients with Intermediate Unfavorable Risk Prostate Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Institut Bergonie

Hypercholesterolaemia

Not recruiting

Study on MK-0616, Ezetimibe, and Bempedoic Acid for Adults with High Cholesterol

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bempedoic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer metastatic

Not recruiting

Study on Ceralasertib and Trastuzumab Deruxtecan for Patients with Non-Small Cell Lung Cancer After Anti-PD-1/PD-L1 Therapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ceralasertib
  • Sponsor:AstraZeneca AB

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Saint-Herblain

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on advanced cancer treatments, including studies for breast cancer, lung cancer, and gastric cancer. Research includes novel therapeutic approaches targeting specific cancer types.

  • Triple-negative breast cancer interventions
  • Non-small cell lung cancer therapies
  • Gastrointestinal cancer treatments

Several trials are evaluating new antibody-drug conjugates and combination therapies for metastatic diseases.

02 Neurological Disorders

Studies targeting various neurological conditions, with emphasis on frontotemporal dementia and multiple sclerosis. Research focuses on innovative therapeutic approaches and disease-modifying treatments.

  • Dementia progression studies
  • Multiple sclerosis treatments
  • Sleep disorder interventions

Trials include evaluation of novel antibodies and assessment of long-term treatment efficacy.

03 Cardiovascular Studies

Comprehensive research into heart failure prevention, pulmonary hypertension, and cardiac rhythm disorders. Studies focus on innovative therapeutic approaches and preventive measures.

  • Heart failure prevention strategies
  • Pulmonary hypertension treatments
  • Cardiac rhythm management

Research includes long-term safety assessments and combination therapy evaluations.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.